Zomedica Pharmaceuticals Corp reported record financial performance for Q1 2026, marking the 21st consecutive quarter of revenue growth. The company achieved $8.8 million in total revenue, a 35% year-over-year increase.
Diagnostics segment revenue surged 73%, driven by strong adoption of the TRUFORMA platform. Therapeutic devices segment remained roughly flat, while development services contributed $2 million.
Zomedica plans to launch new assays in Q3 and Q4 2026, and aims to complete PIMS integration by September 2026. Management targets cash flow breakeven and GAAP profitability by 2027.
Despite lack of forward guidance, the stock saw a 17.9% price change, reflecting positive investor sentiment from strong financial results and strategic progress.
